Characterizing the biological basis of thalamic vulnerability in C9ORF72 ALS-FTD

Active Grant Awarded

Award ID
FAG107070ULEP58
Recipient
Awarding agency
Obligated
$76,300

Award facts

Assistance listing
93.AG4 National Institute on Aging Training Individual Projects
Completion date 2% complete
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

Description

Abstract
C9ORF72 repeat expansions are the most common genetic cause of frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS), characterized by TAR DNA-binding protein 43 (TDP-43) neuropathological inclusions and dipeptide repeat proteins (DPRS). C9ORF72 carriers face approximately equal risk of developing a predominant cognitive/behavioral (FTD) or neuromuscular (ALS) presentation, and no disease-specific biomarkers exist to predict age at onset or clinical phenotype. Reduced thalamic volume on structural MRI is a promising C9ORF72-specific biomarker candidate: presymptomatic thalamic atrophy is unique to C9ORF72 disease relative to sporadic FTD and ALS and thalamic volume outperforms other regional MRI measures in predicting phenoconversion risk. However, the biological basis for this thalamic vulnerability remain unknown, limiting its translational utility. Because TDP-43 pathology is thought to spread through selectively vulnerable neuronal networks, and distinct thalamic nuclei preferentially project to frontal versus motor cortex, nucleus-specific vulnerability may explain the phenotypic divergence between C9+ FTD and ALS. This proposal tests the hypothesis that C9ORF72-specific thalamic vulnerability reflects distinct neuronal subtypes and transcriptomic states within affected nuclei, with differential involvement of frontal- versus motor-projecting nuclei driving phenotypic divergence. Aim 1 uses digital histology to quantify projection-neuron subpopulation integrity and TDP-43 and DPR burden at nucleus resolution across C9+ and sporadic ftld-TDP and ALS cases from the university of pennsylvania brain bank. Aim 2 applies spatial transcriptomics to characterize gene-expression signatures within vulnerable thalamic nuclei across the same groups, enabling spatially resolved interrogation of the focal TDP-43 pathology microenvironments. Together, these aims provide cellular and transcriptomic evidence needed to further establish thalamic MRI vulnerability as a C9ORF72 biomarker and advance understanding of selective neuronal susceptibility across the ALS-FTD spectrum. This fellowship will be conducted at the university of pennsylvania frontotemporal degeneration center under the mentorship of DRS. Corey mcmillan, david irwin and mingyao LI. The training plan is designed to build specialized expertise in digital histology and spatial transcriptomics to complement existing strengths in quantitative neuroimaging and multi- omic data integration. The training plan will position me to submit a K01 career development award focused on developing biologically grounded neuroimaging biomarkers for neurodegenerative disease to enable earlier diagnosis and precision therapeutic interventions.

Quick answers

Who received award FAG107070ULEP58?

FAG107070ULEP58 was awarded to The Trustees Of The University Of Pennsylvania by National Institute on Aging (National Institutes of Health) on November 13, 2026.

How much is award FAG107070ULEP58 worth?

$76,300 has been obligated on FAG107070ULEP58.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award